MIRA Pharmaceuticals, Inc.(MIRA)Earnings, Financials & Key Ratios
MIRA•NASDAQ
$1.00
$40M mkt cap·Price updated May 6, 2026
AboutMIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.Show more
- Revenue$0
- EBITDA-$8M+6.0%
- Net Income-$8M+34.5%
- EPS (Diluted)-0.51+21.5%
- ROE-238.9%+62.3%
- Interest Coverage-48.40-1862.0%
MIRA Key Insights
MIRA Pharmaceuticals, Inc. (MIRA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 16.8% through buybacks
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 15 (bottom 15%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MIRA Price & Volume
MIRA Pharmaceuticals, Inc. (MIRA) stock price & volume — 10-year historical chart
Loading chart...
MIRA Growth Metrics
MIRA Pharmaceuticals, Inc. (MIRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-152.8%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-111.84%
Return on Capital
10 Years-421.86%
5 Years-421.86%
3 Years-497.06%
Last Year-243.94%
MIRA Peer Comparison
MIRA Pharmaceuticals, Inc. (MIRA) competitors in Clinical-stage biotech and oncology — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ATAI | 1B | 4.17 | -4.48 | -1.91% | -51.09% | -96.43% | 0.21 | |
 CMPS | 937.8M | 9.76 | -3.17 | -335.93% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -55.3% | ||||
 CYBN | 303.86M | 6.09 | -13.66 | -81% | ||||
 NRXP | 84.43M | 3.05 | -2.28 | -157.28% | ||||
 SILO | 1.89M | 0.42 | -0.35 | -70.41% | -101.36% | |||
 LPCN | 13.17M | 2.43 | -1.44 | -82.35% | -487.05% | -59.29% | ||
 PSTV | 14.52M | 6.00 | -0.83 | -10.49% | -429.43% | -5.6% | 0.21 |
Compare MIRA vs Peers
MIRA Pharmaceuticals, Inc. (MIRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MIRA Income Statement
MIRA Pharmaceuticals, Inc. (MIRA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 67.63K | 2.15M | 7.05M | 8.53M | 8.02M | 7.11M |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 52.98K | 770.12K | 2.99M | 6.5M | 4.71M | 5.02M |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 14.65K | 684.45K | 2.35M | 1.57M | 3.31M | 2.08M |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 697.6K | 1.7M | 453.55K | 0 | 0 |
| Operating Income | -67.63K▲ 0% | -2.15M▼ 3082.3% | -7.05M▼ 227.5% | -8.53M▼ 21.0% | -8.02M▲ 6.0% | -7.11M▲ 0% |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | -3082.31% | -227.48% | -20.97% | 5.95% | - |
| EBITDA | -67.63K | 0 | 0 | -8.53M | -8.02M | -6.93M |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | - | 100% | - | - | 5.95% | -97.97% |
| D&A (Non-Cash Add-back) | 0 | 2.15M | 7.05M | 0 | -2 | 0 |
| EBIT | -67.63K | -2.15M | -7.05M | -8.53M | -8.02M | -6.93M |
| Net Interest Income | -364 | -24.37K | -10.25K | -3.46M | -165.67K | 83.72K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 83.72K |
| Interest Expense | 364 | 24.37K | 10.25K | 3.46M | 165.67K | 0 |
| Other Income/Expense | -364 | -24.37K | -10.25K | -3.46M | 165.67K | 247.23K |
| Pretax Income | -67.99K▲ 0% | -2.18M▼ 3101.1% | -7.06M▼ 224.3% | -11.98M▼ 69.8% | -7.85M▲ 34.5% | -6.86M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -67.99K▲ 0% | -2.18M▼ 3101.1% | -7.06M▼ 224.3% | -11.98M▼ 69.8% | -7.85M▲ 34.5% | -28.42M▲ 0% |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | - | -3101.12% | -224.29% | -69.77% | 34.46% | -152.8% |
| Net Income (Continuing) | -67.99K | -2.18M | -7.06M | -11.98M | -7.85M | -6.86M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.00▲ 0% | -0.15▼ 3160.9% | -0.48▼ 220.0% | -0.65▼ 35.4% | -0.51▲ 21.5% | -1.47▲ 0% |
| EPS Growth % | - | - | -220% | -35.42% | 21.54% | -111.84% |
| EPS (Basic) | -0.00 | -0.15 | -0.48 | -0.65 | -0.51 | - |
| Diluted Shares Outstanding | 14.75M | 14.75M | 14.75M | 18.57M | 15.44M | 19.27M |
| Basic Shares Outstanding | 14.75M | 14.75M | 14.75M | 18.57M | 15.44M | 19.27M |
| Dividend Payout Ratio | - | - | - | - | - | - |
MIRA Balance Sheet
MIRA Pharmaceuticals, Inc. (MIRA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 3.49K | 2.91M | 494.4K | 4.86M | 2.89M | 7.6M |
| Cash & Short-Term Investments | 3.49K | 2.81M | 350.98K | 4.6M | 2.83M | 2.64M |
| Cash Only | 3.49K | 2.81M | 350.98K | 4.6M | 2.83M | 2.64M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 35.44K |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 0 | 100K | 143.43K | 11.86K | 0 | 4.92M |
| Total Non-Current Assets | 18.88K | 445.61K | 363.67K | 74.21K | 35.44K | 35.44K |
| Property, Plant & Equipment | 0 | 0 | 363.67K | 5.06K | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 35.44K | 106.32K |
| Other Non-Current Assets | 18.88K | 445.61K | 0 | 69.15K | 0 | 35.44K |
| Total Assets | 22.37K▲ 0% | 3.36M▲ 14897.8% | 858.07K▼ 74.4% | 4.93M▲ 474.8% | 2.92M▼ 40.7% | 7.63M▲ 0% |
| Asset Turnover | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 14897.83% | -74.43% | 474.83% | -40.74% | -96.27% |
| Total Current Liabilities | 90.36K | 1.09M | 1.37M | 558.1K | 723.35K | 83.93K |
| Accounts Payable | 0 | 228.41K | 905.55K | 538.56K | 723.35K | 83.93K |
| Days Payables Outstanding | - | - | - | - | - | - |
| Short-Term Debt | 90K | 293.06K | 133.06K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 0.04x | 2.66x | 0.36x | 8.70x | 3.99x | 3.99x |
| Quick Ratio | 0.04x | 2.66x | 0.36x | 8.70x | 3.99x | 3.99x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 84.27K | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 84.27K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 90.36K | 1.09M | 1.45M | 558.1K | 723.35K | 83.93K |
| Total Debt | 90K | 293.06K | 491.23K | 5.06K | 0 | 0 |
| Net Debt | 86.51K | -2.52M | 140.25K | -4.6M | -2.83M | -2.64M |
| Debt / Equity | - | 0.13x | - | 0.00x | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | 0.38x |
| Interest Coverage | -185.79x | -88.30x | -687.60x | -2.47x | -48.40x | - |
| Total Equity | -67.99K▲ 0% | 2.26M▲ 3425.9% | -596.23K▼ 126.4% | 4.37M▲ 833.7% | 2.2M▼ 49.7% | 7.55M▲ 0% |
| Equity Growth % | - | 3425.87% | -126.37% | 833.67% | -49.71% | -71.79% |
| Book Value per Share | -0.00 | 0.15 | -0.04 | 0.24 | 0.14 | 0.39 |
| Total Shareholders' Equity | -67.99K | 2.26M | -596.23K | 4.37M | 2.2M | 7.55M |
| Common Stock | 5.89K | 6.34K | 6.66K | 1.48K | 1.66K | 3.95K |
| Retained Earnings | -67.99K | -2.24M | -9.3M | -21.29M | -29.14M | -33.6M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -5.89K | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
MIRA Cash Flow Statement
MIRA Pharmaceuticals, Inc. (MIRA) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | -67.99K | -1.38M | -5.6M | -4.53M | -5.56M | -5.56M |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | - | -1923.97% | -307.28% | 19.13% | -22.69% | 8.04% |
| Net Income | -67.99K | -2.18M | -7.06M | -11.98M | -7.85M | -28.42M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 1.3M | 2.55M | 0 | 1.04M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 24.37K | 10.25K | 5.54M | 1.92M | 22.65M |
| Working Capital Changes | 0 | 776.01K | 146.58K | -639.69K | 371.25K | -598.75K |
| Change in Receivables | 0 | 0 | 0 | -11.86K | 11.86K | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | -389.52K | 184.78K | -639.42K |
| Cash from Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 71.12K | 4.18M | 3.15M | 8.78M | 3.79M | 3.83M |
| Debt Issued (Net) | 90K | 203.06K | -160K | 1.01M | 0 | 14.47K |
| Equity Issued (Net) | 0 | 1000K | 1000K | 1000K | 1000K | 1.81M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -18.88K | -520.85K | 402.19K | 74.28K | 182.42K | 0 |
| Net Change in Cash | 3.49K▲ 0% | 2.81M▲ 80279.9% | -2.46M▼ 187.6% | 4.25M▲ 272.9% | -1.77M▼ 141.6% | -1.5M▲ 0% |
| Free Cash Flow | -67.99K▲ 0% | -1.38M▼ 1924.1% | -5.6M▼ 307.3% | -4.53M▲ 19.1% | -5.56M▼ 22.7% | -5.33M▲ 0% |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | - | -1924.06% | -307.28% | 19.13% | -22.69% | 9.49% |
| FCF per Share | -0.00 | -0.09 | -0.38 | -0.24 | -0.36 | -0.36 |
| FCF Conversion (FCF/Net Income) | 1.00x | 0.63x | 0.79x | 0.38x | 0.71x | 0.19x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
MIRA Key Ratios
MIRA Pharmaceuticals, Inc. (MIRA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -198.47% | -847.77% | -634.3% | -238.9% | -376.4% |
| Return on Invested Capital (ROIC) | - | - | - | - | -507.35% |
| Debt / Equity | 0.13x | - | 0.00x | - | 0.00x |
| Interest Coverage | -88.30x | -687.60x | -2.47x | -48.40x | - |
| FCF Conversion | 0.63x | 0.79x | 0.38x | 0.71x | 0.19x |
MIRA Frequently Asked Questions
MIRA Pharmaceuticals, Inc. (MIRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
MIRA Pharmaceuticals, Inc. (MIRA) grew revenue by 0.0% over the past year. Growth has been modest.
MIRA Pharmaceuticals, Inc. (MIRA) reported a net loss of $28.4M for fiscal year 2024.
Dividend & Returns
MIRA Pharmaceuticals, Inc. (MIRA) has a return on equity (ROE) of -238.9%. Negative ROE indicates the company is unprofitable.
MIRA Pharmaceuticals, Inc. (MIRA) had negative free cash flow of $5.3M in fiscal year 2024, likely due to heavy capital investments.
Explore More MIRA
MIRA Pharmaceuticals, Inc. (MIRA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates